Nike Earnings at Risk as UBS Cuts Price Target to $42 
Meta CEO Zuckerberg Backs Independent AI Safety Reviews Over Development Slowdown 
Supertanker Orders Surge as US-Iran War Reshapes Oil Trade 
SpaceX Nasdaq 100 Weight to More Than Double in Rebalance 
Gold Prices Rise as Oil and Treasury Yields Fall 
Volkswagen Shares Slide After 2026 Profit Outlook Cut 
BOJ Raises Interest Rate to 31-Year High as Yen Weakens 
Strait of Hormuz Oil Shipments Hit Six-Month High as U.S. Clears Mines 
Asian Gold Stocks Rise as Bullion Rebounds on Softer Dollar 
Bessent Presses Japan on Fiscal Policy as Yen Struggles 
White House Bars CNN, MS NOW and Politico Reporters 
US Stock Futures Dip After Wall Street Rally 
South Korea Producer Prices Rise 0.2% in August 
US Federal Register Drops Alibaba Qwen AI Search Tool 
Canada Eyes India Trade Deal by Year-End 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Japan, U.S. Discuss $19 Billion GlobalFoundries Chip Plant 
Add as a preferred source on Google
COVID-19 vaccines are expensive but a new alternative is coming and this will cut the costs. A division of the Japanese pharma company, Mitsubishi Tanabe Pharma Company, has developed the world’s first plant-based coronavirus vaccine and is looking to launch it soon.
The Medicago biopharmaceutical company that is owned by Mitsubishi Tanabe said that its new COVID-19 vaccine would be cheaper and easier to move compared to the conventional types since this is plant-based. It was also mentioned that Medicago is also backed by the Marlboro producer, Philip Morris International.
According to the Financial Times, the head of Mitsubishi Tanabe Pharma’s vaccine business development, Toshifumi Tada, revealed that Medicago would be applying for approval of its plant-based vaccine in Canada by the end of this year.
With its successful development of the alternative COVID-19 vaccine, the Osaka headquartered pharmaceutical firm is expecting global demand for the product. The company also believes that the demand will remain strong since medical professionals continue to detect new strains of the highly contagious coronavirus.
It was noted that no single plant-based vaccine had been approved yet for use in humans, but supporters of the new technology stated that such a type of vaccine is very appealing since plant leaves grow quickly. This fact alone makes the production process cheaper and faster.
Traditional flu vaccines usually take around eight to 12 months to produce but Medicago’s plant-based alternative will only take up five to eight weeks. Plus, the vaccines do not need to be deep-frozen while being transported, as they can be stored at 2C to 8C temperatures.
“Compared to alternative production systems, our proprietary plant-based manufacturing platform has many advantages, including faster lead time, scalability, and versatility,” Medicago’s senior director of scientific and medical affairs, Nathalie Charland, said via the Nature Research Journal. “The rapid nature of our vaccine and therapeutic protein production unlocks many potential ways in which we can better respond to infectious diseases and public health challenges.”
Meanwhile, Medicago will partner with GlaxoSmithKline for the phase 3 trial for its plant-based vaccine in Canada, U.S., the U.K, Mexico, Brazil, and Argentina. The trial is said to involve 24,000 subjects in all.
